Valuation: Edesa Biotech, Inc.

Market Cap 26.21M 23.75M 21.97M 19.82M 37.36M 2.47B 38.67M 264M 105M 1.32B 98.37M 96.28M 4.19B P/E 2026 *
-0.98x
P/E 2027 * -0.94x
Enterprise Value 26.21M 23.75M 21.97M 19.82M 37.36M 2.47B 38.67M 264M 105M 1.32B 98.37M 96.28M 4.19B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
86.11%
Yield 2026 *
-
Yield 2027 * -
1 day-6.73%
1 week-9.35%
Current month-24.51%
1 month-31.81%
3 months-64.27%
6 months-87.27%
Current year+36.62%
1 week 1.76
Extreme 1.76
3.93
1 month 1.76
Extreme 1.76
3.93
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
48.97
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 2015-07-31
Director of Finance/CFO 57 2025-04-30
President 48 2019-06-06
Director TitleAgeSince
Chairman 50 2019-06-06
Director/Board Member 55 2019-06-06
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap. Importance
11/4/26 Free

Chief Executive Officer

18,677 0.1382%
10/28/26 Free

Chief Executive Officer

27,602 0.2044%
10/5/26 Free

Founder

6,893 0.0510%
Change 5-day change 1-year change 3-year change Capi.($)
-6.73%-9.35%+12.14%-23.92% 26.21M
-2.69%-0.48%+51.67%+69.09% 66.33B
-0.92%+7.67%+14.26%+90.92% 60.62B
0.00%+0.39%+20.52%+98.45% 55.5B
+0.14%+2.35%+13.08%+109.47% 47.58B
-2.21%-2.47%+18.60%+36.89% 43.69B
-2.30%-10.40%+167.61%+776.79% 37.27B
+2.15%+1.42%+15.17%+56.49% 36.57B
-2.32%-2.24%+75.52%+52.70% 32.22B
+2.62%+5.90%-36.55%+406.95% 26.58B
Average -1.23%-1.37%+35.20%+167.38% 41B
Weighted average by Cap. -0.83%-0.52%+37.23%+162.18%

Financials

2026 *2027 *
Net sales - -
Net income -17.52M -15.88M -14.69M -13.25M -24.98M -1.65B -25.86M -176M -69.97M -883M -65.76M -64.37M -2.8B -23.88M -21.64M -20.01M -18.06M -34.03M -2.25B -35.23M -240M -95.33M -1.2B -89.61M -87.71M -3.82B
Net Debt - -
Projected Income Statement - Annual - Edesa Biotech, Inc.
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
-
Date Price Change Volume
26-11-13 US$1.940 -6.73% 510,770
26-11-12 US$2.080 -6.31% 520,659
26-11-11 US$2.220 +9.90% 1,017,949
26-11-10 US$2.020 -18.88% 2,121,068
26-11-09 US$2.490 +16.36% 84,578,525
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Edesa Biotech, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.940USD
Average target price
16.33USD
Spread / Average Target
+741.92%
  1. Stock Market
  2. Stocks
  3. EDSA Stock